Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | MIF | P14174 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL766884 | 0.90 | TP53 (0.41) | TP53ATMKCNN4ACHEMIF | |
| Iodide SCHEMBL2950357 | 0.87 | TP53 (0.39) | TP53ATMKCNN4ACHEMIF | |
| Hydrochloric Acid SCHEMBL60378 | 0.87 | TP53 (0.39) | TP53ATMKCNN4ACHEMIF | |
| SCHEMBL11346122 | 0.82 | TP53 (0.32) | TP53ATMKCNN4MEN1KMT2A | |
| SCHEMBL11448241 | 0.82 | TP53 (0.32) | TP53ATMKCNN4 | |
| SCHEMBL2734098 | 0.78 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL767137 | 0.77 | ATM (0.34) | TP53ATMKCNN4LMNASMN1; SMN2 | |
| SCHEMBL12818240 | 0.77 | ACHE (0.31) | ACHE | |
| SCHEMBL11346850 | 0.77 | GPR84 (0.37) | TP53LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL11312789 | 0.76 | MGLL (0.36) | TP53LMNAHTTSMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117024411-B | Isoquinoline as HPK1 inhibitor | 豪夫迈·罗氏有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | GENENTECH, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12465643-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250319187-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12409225-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-09-09 | — | — | US | disclosed |
| US-12403196-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255964-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-08-14 | — | — | US | disclosed |
| US-20250242029-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| US-20250195662-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-06-19 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-4962179-A | CURABLE COMPOSITION INCLUDING AROMATIC AMINE CURING AGENT AND AN ACIDIC OR METAL COMPOUND ACCELORATOR; POT LIFE; MOLDING MATERIALS; THERMOLATENCY; POLYEPOXIDES | SHELL OIL COMPANY (US) | 1990-10-09 | — | — | US | disclosed |
| EP-0355924-A2 | Curable epoxy resin composition | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1990-02-28 | — | — | EP | disclosed |
| US-4874833-A | ELECTRICAL LAMINATE | SHELL OIL COMPANY (US) | 1989-10-17 | — | — | US | disclosed |
| EP-0195138-A2 | Heat-curable epoxy composition | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-09-24 | — | — | EP | disclosed |
| US-4581436-A | POLYEPOXIDE, AROMATIC OR ALIPHATIC AMINE;TRIHYDROCARBYL SULFONIUM SALT, UNSATURATED MONOMER AND FREE RADICAL CURING AGENT;MOLDING MATERIALS | SHELL OIL COMPANY (US) | 1986-04-08 | — | — | US | disclosed |
| US-4579931-A | CURING POLYEPOXIDES WITH AMINES, SULFONIUM SALTS, FREE RAPICAL CATALYST, UNSATURATED DILVENTS | SHELL OIL COMPANY (US) | 1986-04-01 | — | — | US | disclosed |
| EP-0170333-A2 | Heat-curable compositions comprising an epoxy resin, an amine and a sulphonium salt | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1986-02-05 | — | — | EP | disclosed |
| US-4554342-A | Heat-curable compositions comprising an epoxy resin, an amine and a sulfonium salt | SHELL OIL COMPANY (US) | 1985-11-19 | — | — | US | disclosed |
| US-4544732-A | POLYEPOXIDE, AMINE, TRIHYDROCARBYL SULFONIUM SALT, UNSATURATED AROMATIC MONOMER, AND FREE RADICAL CURING AGENTS | SHELL OIL COMPANY (US) | 1985-10-01 | — | — | US | disclosed |
| EP-0021160-A1 | Process for the preparation of trans-3,3-dimethyl-cyclopropane-1,2-dicarboxylic acid | BAYER AG (DE) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473301-B2 | Isoquinoline compounds for the treatment of cancer | PGK1, PHKG1, NEK1 | TP53 531/4885ATM 295/4885KCNN4 3839/4885 |
| US-20250195662-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TP53 9/4885ATM 1568/4885KCNN4 4829/4885 |
| US-20250319187-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TP53 9/4885ATM 1568/4885KCNN4 4829/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | TP53 119/4885ATM 858/4885KCNN4 4198/4885 |
| US-20250255964-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TP53 9/4885ATM 1568/4885KCNN4 4829/4885 |
| US-12403196-B2 | Ras inhibitors | KRAS, NRAS, HRAS | TP53 9/4885ATM 1568/4885KCNN4 4829/4885 |
| US-12465643-B2 | Ras inhibitors | KRAS, NRAS, HRAS | TP53 9/4885ATM 1568/4885KCNN4 4829/4885 |
| US-20250242029-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | TP53 9/4885ATM 1568/4885KCNN4 4829/4885 |
| US-12409225-B2 | Ras inhibitors | KRAS, NRAS, HRAS | TP53 9/4885ATM 1568/4885KCNN4 4829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.